QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

$1.22
+0.03 (+2.52%)
(As of 04:23 PM ET)
Today's Range
$1.15
$1.29
50-Day Range
$1.14
$1.78
52-Week Range
$0.53
$3.29
Volume
5,226 shs
Average Volume
61,491 shs
Market Capitalization
$20.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

RenovoRx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
596.7% Upside
$8.50 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of RenovoRx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.93 out of 5 stars

Medical Sector

806th out of 919 stocks

Pharmaceutical Preparations Industry

359th out of 410 stocks

RNXT stock logo

About RenovoRx Stock (NASDAQ:RNXT)

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

RNXT Stock Price History

RNXT Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
RenovoRx announces key leadership promotions
RenovoRx annonce des promotions à des postes clés
RenovoRx Highlights Key Leadership Promotions
RenovoRx closes $6.1M private placement
RenovoRx Closes $6.1 Million Private Placement
RenovoRx Inc RNXT
Maxim Group Downgrades RenovoRx (RNXT)
RenovoRx GAAP EPS of -$0.13
See More Headlines
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNXT
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$13.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+596.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.28) per share

Miscellaneous

Free Float
15,348,000
Market Cap
$20.58 million
Optionable
Not Optionable
Beta
1.04
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

RNXT Stock Analysis - Frequently Asked Questions

Should I buy or sell RenovoRx stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RNXT shares.
View RNXT analyst ratings
or view top-rated stocks.

What is RenovoRx's stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for RenovoRx's shares. Their RNXT share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 596.7% from the stock's current price.
View analysts price targets for RNXT
or view top-rated stocks among Wall Street analysts.

How have RNXT shares performed in 2024?

RenovoRx's stock was trading at $2.29 on January 1st, 2024. Since then, RNXT shares have decreased by 46.7% and is now trading at $1.22.
View the best growth stocks for 2024 here
.

When is RenovoRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RNXT earnings forecast
.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNXT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners